RxDoctor Payments Data

Danisha Stevenson, MD

Family Medicine · Fleming Island, FLNPI 1649620261

Payments from drug & device makers

$9,655in general payments, 2019–2025

Across 584 payments — averaging $16.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • AstraZeneca$803
  • GSK$762
  • Lilly USA, LLC$632
  • Amgen$575
  • plus $3K from 42 others

What the payments were for

  • Food & beverage$9,55599%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,655 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$135,822
Medicare patients
301
Services billed
1,923

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide60$56,688
MounjaroTirzepatide33$43,538
FarxigaDapagliflozin Propanediol42$40,567
EliquisApixaban31$36,129
UbrelvyUbrogepant21$33,174
JanuviaSitagliptin Phosphate19$23,878
TrulicityDulaglutide20$19,906
MyrbetriqMirabegron13$12,448
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$11,972
Spiriva RespimatTiotropium Bromide13$8,347
Praluent PenAlirocumab13$6,134
SynthroidLevothyroxine Sodium35$4,063
Atorvastatin Calcium231$2,449
Omeprazole109$2,178
Gabapentin83$1,939

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$632$63,44453 claims
Novo NordiskOzempic$1,281$56,68860 claims
AstraZenecaFarxiga$803$40,56742 claims
AbbVieUbrelvy, Synthroid$2,220$37,23656 claims
PfizerEliquis$247$36,12931 claims
MerckJanuvia$104$23,87819 claims
Astellas Pharma US IncMyrbetriq$182$12,44813 claims
GSKTrelegy Ellipta$762$11,97218 claims
Boehringer IngelheimSpiriva Respimat$381$8,34713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Fleming Island

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →